-
摘要:
目的 探讨肌腱蛋白-C（TNC）与肝移植术后早期急性排斥反应（AR）的关系。 方法 将6只Brown Norway（BN）大鼠和16只Lewis大鼠分为AR组（Lewis→BN，供、受体各6只）和对照组（Lewis→Lewis，供、受体各5只）。对两组大鼠移植肝组织进行病理学检查，采用Banff分级评估排斥活动指数（RAI）；采用免疫组织化学（免疫组化）染色、蛋白质印迹法检测两组大鼠移植肝TNC蛋白表达情况；采用酶联免疫吸附试验（ELISA）检测血清TNC表达水平，并分析其与RAI评分的相关性。 结果 大鼠肝移植术后7 d移植肝病理学结果显示AR组RAI评分高于对照组；免疫组化结果显示术后7 d AR组移植肝TNC阳性细胞分布多于对照组；蛋白质印迹法结果显示术后7 d AR组移植肝TNC蛋白相对表达量高于对照组（t=5.112，P=0.007）；ELISA结果显示术后7 d AR组血清TNC表达水平高于对照组（t=3.152，P=0.012），且血清TNC表达水平与RAI评分呈正相关（r=0.790 9，P=0.004）。 结论 肝移植术后TNC表达水平与AR相关，TNC有可能成为临床肝移植术后早期AR诊断和治疗的新靶点。 Abstract:Objective To investigate the relationship between tenascin-C (TNC) and acute rejection (AR) early after liver transplantation. Methods Six Brown Norway (BN) rats and 16 Lewis rats were divided into the AR group (Lewis→BN, 6 donors and 6 recipients) and control group (Lewis→Lewis, 5 donors and 5 recipients). The transplant liver tissues from rats in two groups were subjected to pathological examination. The rejection activity index (RAI) was evaluated by Banff schema. The expression of TNC proteins in the transplant liver tissues were determined by immunohistochemical staining and Western blot. The expression level of serum TNC was detected by enzyme-linked immune absorbent assay (ELISA), and the correlation between TNC and RAI score was analyzed. Results Pathological examination of the transplant liver at 7 d after liver transplantation showed that the RAI score in the AR group was higher than that in the control group. Immunohistochemical staining results found that the distribution of TNC positive cells of the transplant liver in the AR group was more than that in control group at postoperative 7 d. Western blot showed that the relative expression level of TNC protein in the AR group was significantly higher than that in the control group at 7 d after liver transplantation (t=5.112, P=0.007). ELISA results revealed that the serum TNC expression level in the AR group was significantly higher than that in the control group at 7 d after liver transplantation (t=3.152, P=0.012). The serum TNC expression level was positively correlated with the RAI score (r=0.790 9, P=0.004). Conclusions The expression level of TNC is associated with AR after liver transplantation. TNC may become a novel target for diagnosis and treatment of AR early after liver transplantation. -
图 1 两组大鼠移植肝组织病理学表现（HE，×200）
注：A图为对照组；B图为AR组。
Figure 1. Pathological findings of liver allograft tissuesof rats in two groups
图 2 两组大鼠移植肝组织TNC阳性细胞分布情况（免疫组化，×200）
注：A图为对照组；B图为AR组。
Figure 2. Distribution of TNC positive cells of liver allograft tissues of rats in two groups
图 3 两组大鼠移植肝组织TNC蛋白相对表达量
注：A图为两组大鼠移植肝组织蛋白质印迹图片；B图为两组大鼠移植肝组织TNC蛋白相对表达量的比较，与对照组比较，aP < 0.05。
Figure 3. Relative protein expression level of TNC of liver allograft tissues of rats in two groups
-
[1] 沈中阳. 中国肝移植的发展与创新[J]. 临床肝胆病杂志, 2019, 35(11): 2377-2385. DOI: 10.3969/j.issn.1001-5256.2019.11.001.SHEN ZY. Development and innovation of liver transplantation in China[J]. J Clin Hepatol, 2019, 35(11): 2377-2385. DOI: 10.3969/j.issn.1001-5256.2019.11.001. [2] 石炳毅. 继往开来, 中国器官移植的发展现状——在2018年中华医学会器官移植学年会上的报告[J]. 器官移植, 2019, 10(1): 32-35. DOI: 10.3969/j.issn.1674-7445.2019.01.004.SHI BY. Development status of organ transplantation in China: the report on the 2018 Annual Meeting of Organ Transplantation of Chinese Medical Association[J]. Organ Transplant, 2019, 10(1): 32-35. DOI: 10.3969/j.issn.1674-7445.2019.01.004. [3] 卢中山, 王伟, 钟自彪, 等. 肝脏缺血再灌注损伤干预措施的研究进展[J]. 中华肝胆外科杂志, 2019, 25(11): 871-874. DOI: 10.3760/cma.j.issn.1007-8118.2019.11.020.LU ZS, WANG W, ZHONG ZB, et al. Advances in intervention measures for hepatic ischemia-reperfusion injury[J]. Chin J Hepatobiliary Surg, 2019, 25(11): 871-874. DOI: 10.3760/cma.j.issn.1007-8118.2019.11.020. [4] ALLISON SJ. Nanosensors enable early detection of acute T cell-mediated rejection of transplants[J]. Nat Rev Nephrol, 2019, 15(5): 253. DOI: 10.1038/s41581-019-0134-7. [5] TONIUTTO P, ZANETTO A, FERRARESE A, et al. Current challenges and future directions for liver transplantation[J]. Liver Int, 2017, 37(3): 317-327. DOI: 10.1111/liv.13255. [6] BENSELER V, MCCAUGHAN GW, SCHLITT HJ, et al. The liver: a special case in transplantation tolerance[J]. Semin Liver Dis, 2007, 27(2): 194-213. DOI: 10.1055/s-2007-979471. [7] ABU-GAZALA S, OLTHOFF KM. Status of adult living donor liver transplantation in the United States: results from the adult-to-adult living donor liver transplantation cohort study[J]. Gastroenterol Clin North Am, 2018, 47(2): 297-311. DOI: 10.1016/j.gtc.2018.01.004. [8] CHARLTON M, LEVITSKY J, AQEL B, et al. International Liver Transplantation Society consensus statement on immunosuppression in liver transplant recipients[J]. Transplantation, 2018, 102(5): 727-743. DOI: 10.1097/TP.0000000000002147. [9] VON PLATEN A, D'SOUZA MA, ROOYACKERS O, et al. Intrahepatic microdialysis for monitoring of metabolic markers to detect rejection early after liver transplantation[J]. Transplant Proc, 2020, 53(1): 130-135. DOI: 10.1016/j.transproceed.2020.02.157. [10] BABA HA, THEURER S, CANBAY A, et al. Liver transplantation. current aspects of pretransplantation diagnosis and rejection[J]. Pathologe, 2020, 41(5): 505-514. DOI: 10.1007/s00292-020-00813-9. [11] TUCKER RP, CHIQUET-EHRISMANN R. Tenascin-C: its functions as an integrin ligand[J]. Int J Biochem Cell Biol, 2015, 65: 165-168. DOI: 10.1016/j.biocel.2015.06.003. [12] LOWY CM, OSKARSSON T. Tenascin C in metastasis: a view from the invasive front[J]. Cell Adh Migr, 2015, 9(1/2): 112-124. DOI: 10.1080/19336918.2015.1008331. [13] TANABE S, UEDA M, HAN YS, et al. Increased tenascin expression is an early feature of the development of transplant renal arteriopathy in humans[J]. Transpl Int, 1996, 9(Suppl 1): S45-S48. DOI: 10.1007/978-3-662-00818-8_13. [14] CHEN S, FU H, WU S, et al. Tenascin-C protects against acute kidney injury by recruiting Wnt ligands[J]. Kidney Int, 2019, 95(1): 62-74. DOI: 10.1016/j.kint.2018.08.029. [15] KAMADA N. The immunology of experimental liver transplantation in the rat[J]. Immunology, 1985, 55(3): 369-389. [16] ROUFOSSE C, SIMMONDS N, CLAHSEN-VAN GRONINGEN M, et al. A 2018 reference guide to the Banff classification of renal allograft pathology[J]. Transplantation, 2018, 102(11): 1795-1814. DOI: 10.1097/TP.0000000000002366. [17] AGOPIAN VG, HARLANDER-LOCKE MP, MARKOVIC D, et al. Evaluation of early allograft function using the liver graft assessment following transplantation risk score model[J]. JAMA Surg, 2018, 153(5): 436-444. DOI: 10.1001/jamasurg.2017.5040. [18] KRENZIEN F, KESHI E, SPLITH K, et al. Diagnostic biomarkers to diagnose acute allograft rejection after liver transplantation: systematic review and Meta-analysis of diagnostic accuracy studies[J]. Front Immunol, 2019, 10: 758. DOI: 10.3389/fimmu.2019.00758. [19] KOK B, DONG V, KARVELLAS CJ. Graft dysfunction and management in liver transplantation[J]. Crit Care Clin, 2019, 35(1): 117-133. DOI: 10.1016/j.ccc.2018.08.002. [20] KOHUT TJ, BARANDIARAN JF, KEATING BJ. Genomics and liver transplantation: genomic biomarkers for the diagnosis of acute cellular rejection[J]. Liver Transpl, 2020, 26(10): 1337-1350. DOI: 10.1002/lt.25812. [21] RODRIGO E, CHEDID MF, SEGUNDO DS, et al. Acute rejection following kidney transplantation: state-of-the-art and future perspectives[J]. Curr Pharm Des, 2020, 26(28): 3468-3496. DOI: 10.2174/1381612826666200610184433. [22] 王朝阳, 朱美意, 欧阳军, 等. Neuritin与HSP60在急性肝损伤修复中的表达变化及意义[J]. 实用医学杂志, 2018, 34(12): 1959-1964, 1969. DOI: 10.3969/j.issn.1006-5725.2018.12.010.WANG CY, ZHU MY, OUYANG J, et al. Expression and significance of Neuritin and HSP60 in repair of acute liver injury[J]. J Pract Med, 2018, 34(12): 1959-1964, 1969. DOI: 10.3969/j.issn.1006-5725.2018.12.010. [23] WEI Q, WANG K, YANG M, et al. Recipient gender and body mass index are associated with early acute rejection in donation after cardiac death liver transplantation[J]. Clin Res Hepatol Gastroenterol, 2020, 44(Suppl): 100004. DOI: 10.1016/j.clirex.2020.100004. [24] MARZEDA AM, MIDWOOD KS. Internal affairs: tenascin-C as a clinically relevant, endogenous driver of innate immunity[J]. J Histochem Cytochem, 2018, 66(4): 289-304. DOI: 10.1369/0022155418757443. [25] CHIQUET M. Tenascin-C: from discovery to structure-function relationships[J]. Front Immunol, 2020, 11: 611789. DOI: 10.3389/fimmu.2020.611789. [26] BENBOW JH, ELAM AD, BOSSI KL, et al. Analysis of plasma tenascin-C in post-HCV cirrhosis: a prospective study[J]. Dig Dis Sci, 2018, 63(3): 653-664. DOI: 10.1007/s10620-017-4860-z. [27] BENBOW JH, THOMPSON KJ, COPE HL, et al. Diet-induced obesity enhances progression of hepatocellular carcinoma through tenascin-C/Toll-like receptor 4 signaling[J]. Am J Pathol, 2016, 186(1): 145-158. DOI: 10.1016/j.ajpath.2015.09.015. [28] KURIYAMA N, DUARTE S, HAMADA T, et al. Tenascin-C: a novel mediator of hepatic ischemia and reperfusion injury[J]. Hepatology, 2011, 54(6): 2125-2136. DOI: 10.1002/hep.24639. [29] MOMČILOVIĆ M, STAMENKOVIĆ V, JOVANOVIĆ M, et al. Tenascin-C deficiency protects mice from experimental autoimmune encephalomyelitis[J]. J Neuroimmunol, 2017, 302: 1-6. DOI: 10.1016/j.jneuroim.2016.12.001. [30] ZHAO YY, LOU L, YANG KC, et al. Correlation of tenascin-C concentrations in serum with outcome of traumatic brain injury in humans[J]. Clin Chim Acta, 2017, 472: 46-50. DOI: 10.1016/j.cca.2017.07.018. -
下载:
点击查看大图
图(6)
计量
- 文章访问数: 463
- HTML全文浏览量: 124
- PDF下载量: 48
- 被引次数: 0
